Phase IIa Trial Reports 3-6 Year Biological Age Reduction
Rentosertib in IPF patients showed statistically significant biological age reductions across six proteomic clocks, with peak effects of 3-4 years at the 30 mg twice-daily dose.
A Phase IIa trial reported biological age reversal on six independent proteomic clocks — the strongest clinical signal senomorphic interventions have produced. Meanwhile, semaglutide extended lifespan in female mice (but not males), and a Science paper argued biological aging is too personal for any single score to capture universally. The bottom line: the tools to measure, and possibly slow, biological aging are converging faster than the field's ability to define what younger means at the molecular level.
Rentosertib in IPF patients showed statistically significant biological age reductions across six proteomic clocks, with peak effects of 3-4 years at the 30 mg twice-daily dose.
A Nature study found semaglutide extended median lifespan by ~18% in female mice when treatment began at 18 months. Male mice showed no significant effect.
A Science study found dramatically different patterns of molecular change across same-age people, concluding biological aging unfolds as individual trajectories shaped by genetics, exposures, and daily rhythms.
A meta-analysis of three cohorts found centenarian offspring had 42% lower all-cause mortality and a 5.2-year hypertension delay, persisting after lifestyle controls.
Protein misfolding amplification in blood plasma detected trace misfolded amyloid-beta with 93% diagnostic accuracy.
Suppressing growth hormone signalling beginning at middle age was sufficient to produce ~15% lifespan extension, narrowing the required intervention window.
Creatine monohydrate in older adults produced measurable improvements in lean muscle mass and cognitive assessments over 16 weeks without concurrent resistance training.
Inhibiting the PGAM1-CHK1 interaction selectively triggers apoptosis in senescent cells while sparing normal cells. The metabolic dependency is in the DNA damage response pathway.
Specific CD8+ T-cell immune signatures predicted subclinical atherosclerotic plaque development three years before imaging confirmation.
Three proteomic clocks showed concordant mortality signal when biological age exceeded chronological age by 7+ years, independent of smoking, BMI, diabetes, and CVD history.
One email a week. The ten things in AI that mattered, and why. Choose your channel.